Abstract 20845: Efficacy and Safety of Intensive Statin Therapy for Hypercholesterolemic Patients With Bioprosthetic Aortic Valve Replacement for Aortic Valve Stenosis
Introduction: Intensive rather than standard statin therapy has been proven to be superior in improving cardiovascular outcome, whereas the effects of intensive statin therapy on inflammation and lipoprotein biomarkers are not well defined.
Hypothesis: The purpose of this study was to validate the efficacy of intensive statin therapy for hypercholesterolemic patients with bioprosthetic aortic valve replacement for aortic valve stenosis.
Methods: In this study, we performed a single-center, randomized, single-blind clinical trial. A total of 30 hypercholesterolemic patients with bioprosthetic aortic valve replacement were enrolled and randomly divided into two groups [intensive-dose rosuvastatin therapy (target LDL-C level: 70 mg/dl) and standard-dose rosuvastatin therapy (target LDL-C level: 120 mg/dl). Evaluation variables, including changes in serum lipid profile, aortic valve area, and E/e’ representing left ventricular diastolic function, from baseline to years 1 and 2, were used to compare the benefits of these two statin therapies.
Results: At baseline, there were no differences between the two groups, including in LDL-C level (intensive 121+/-27 vs. standard 118+/-31, n.s.), aortic valve area (intensive 1.58+/-0.47 vs. standard 1.54+/-0.42, n.s.), and E/e’ (intensive 19+/-20 vs. standard 20+/-10, n.s.). After 4 years of treatment, improvements of LDL-C level (intensive 75+/-11 vs. standard 115+/-10, p<0.001), aortic valve area (intensive 1.63+/-0.24 vs. standard 1.43+/-0.32, n.s.), and E/e’ (intensive 16+/-6 vs. standard 23+/-8, p<0.05) were all better in the intensive group.
Conclusions: Compared with standard statin therapy, long-term intensive-dose statin appears to be safe and lowered the LDL-C level significantly, further improved left ventricular diastolic function, and preserved bioprosthetic aortic valve. Clinical trial registration number. UMIN000006887.
Author Disclosures: Y. Morimoto: None. T. Sugimoto: None. K. Fukase: None.
- © 2016 by American Heart Association, Inc.